BioSpace News Archive

Baxter International Inc. (NYSE:BAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023.

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2023 on Wednesday, April 26, 2023 at 8:00 a.m. EDT.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluphenazine Hydrochloride Tablets, USP in 1 mg, 2.5 mg, 5 mg, and 10 mg strengths.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended December 31, 2022 and provided a business update.

TransCode Therapeutics, Inc. announced that it has entered into a definitive securities purchase agreement with Triton Funds, LP for the sale of 60 shares of the Company’s Series A Convertible Preferred Stock, each with a stated value of $10,000 per share, for an aggregate purchase price of $500,000 in a registered direct offering.

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D today announced financial results for the fourth quarter ended December 31, 2022 and provided a corporate update on key programs.

A group of longstanding shareholders of Sernova Corp who currently own approximately 12% of the Company’s shares have concerns regarding the performance of Sernova’s Board.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”) announces the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial to evaluate KB-GDT-01, or Deltacel, in combination with an anti-tumor therapy for the treatment of non-small cell lung cancer (NSCLC).

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2023, which is being held April 19-23 in Miami, Florida.